Shire success will support polysialic acid drug delivery platform, says Xenetic 06-Apr-2017 By Dan Stanton Xenetic Biosciences says success for Shire’s haemophilia A candidate SHP656 will validate its PolyXen drug delivery technology platform and could net the firm up to $100m.